WO1997010239A1 - Acid addition salts of 2,3,4,5-tetrahydro-1h-3-benzazepine compounds - Google Patents
Acid addition salts of 2,3,4,5-tetrahydro-1h-3-benzazepine compounds Download PDFInfo
- Publication number
- WO1997010239A1 WO1997010239A1 PCT/DK1996/000383 DK9600383W WO9710239A1 WO 1997010239 A1 WO1997010239 A1 WO 1997010239A1 DK 9600383 W DK9600383 W DK 9600383W WO 9710239 A1 WO9710239 A1 WO 9710239A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tetrahydro
- dichloro
- chloro
- methyl
- dihydrobenzofuran
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims abstract description 30
- 239000002253 acid Substances 0.000 title claims description 10
- MWVMYAWMFTVYED-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1h-3-benzazepine Chemical class C1CNCCC2=CC=CC=C21 MWVMYAWMFTVYED-UHFFFAOYSA-N 0.000 title 1
- XTBPVXNRDRWQNN-ZDUSSCGKSA-N (5s)-8-chloro-5-(5,6-dichloro-2,3-dihydro-1-benzofuran-7-yl)-3-methyl-1,2,4,5-tetrahydro-3-benzazepin-7-ol Chemical class C1N(C)CCC2=CC(Cl)=C(O)C=C2[C@H]1C1=C(OCC2)C2=CC(Cl)=C1Cl XTBPVXNRDRWQNN-ZDUSSCGKSA-N 0.000 claims abstract description 19
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 10
- 102000004076 Dopamine D1 Receptors Human genes 0.000 claims description 8
- 108090000511 Dopamine D1 Receptors Proteins 0.000 claims description 8
- 230000004064 dysfunction Effects 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 7
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- IWYDHOAUDWTVEP-ZETCQYMHSA-M (S)-mandelate Chemical compound [O-]C(=O)[C@@H](O)C1=CC=CC=C1 IWYDHOAUDWTVEP-ZETCQYMHSA-M 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- 239000001358 L(+)-tartaric acid Substances 0.000 claims description 2
- 235000011002 L(+)-tartaric acid Nutrition 0.000 claims description 2
- FEWJPZIEWOKRBE-LWMBPPNESA-N L-(+)-Tartaric acid Natural products OC(=O)[C@@H](O)[C@H](O)C(O)=O FEWJPZIEWOKRBE-LWMBPPNESA-N 0.000 claims description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000001530 fumaric acid Substances 0.000 claims description 2
- 239000011976 maleic acid Substances 0.000 claims description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-N mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 abstract description 3
- 150000001875 compounds Chemical class 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000000203 mixture Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- -1 2,3,4,5-tetrahydro-1 H-3-benzazepine Compounds Chemical class 0.000 description 4
- 238000000921 elemental analysis Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- 208000028017 Psychotic disease Diseases 0.000 description 3
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- MHMRQHMKGYLQKH-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1h-3-benzazepin-7-ol Chemical compound C1CNCCC2=CC(O)=CC=C21 MHMRQHMKGYLQKH-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 208000027753 pain disease Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000001090 anti-dopaminergic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical class C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Definitions
- the present invention relates to crystalline salts of (S) ( + )-8-chloro-5- (5,6-dichloro-2,3-dihydrobenzofuran-7-yl)-3-methyl-2,3,4,5-tetrahydro- 1 H-3-benzazepine-7-ol, their preparation and use as therapeutic agents.
- the compound of formula I is used as a therapeutic agent in the form of an acid addition salt. Further, it has been found that some acid addition salts of the compound of formula I do form alternate polymorphic forms. This is pharmaceuti ⁇ cally undesirable because of the potential that the salt occurs in more than one crystalline form making it very difficult to predict how the various parts of the body will react to the different crystalline forms.
- the present invention provides a series of crystalline salts of
- Preferred salts of the invention are (S) ( + )-8-chloro-5-(5,6-dichloro-2,3- dihydrobenzofuran-7-yl)-3-methyl-2,3,4,5-tetrahydro-1 H-3-benzazepin-7- ol, hemifumarate; (S) ( + )-8-chloro-5-(5,6-dichloro-2,3-dihydrobenzofu- ran-7-yl)-3-methyl-2,3,4,5-tetrahydro-1 H-3-benzazepin-7-ol, L( + )-hemi- tartrate; (S) ( + )-8-chloro-5-(5,6-dichloro-2,3-dihydrobenzofuran-7-yl)-3- methyl-2, 3, 4,5-tetrahydro-1 H-3-benzazepin-7-ol, maleate; (S) ( + )-8- chloro-5-(5, 6-dichloro-2,3-di
- the acid addition salts of the (S) ( + )-8-chloro-5-(5,6-dichloro-2,3-dihy- drobenzofuran-7-yl)-3-methyl-2,3,4,5-tetrahydro- 1 H-3-benzazepi ⁇ e-7-ol are prepared by dissolving the acid of the corresponding addition salt and the compound of formula I in a common solvent, and crystallizing the resulting salt from the solution.
- Examples of the common solvents include lower aliphalic alcohols such as ethanol, methanol, 2-propanol, 2-butanol, 1 -hexanol and solvents like isobutylmethylketone and tetrahydrofuran.
- lower aliphalic alcohols such as ethanol, methanol, 2-propanol, 2-butanol, 1 -hexanol and solvents like isobutylmethylketone and tetrahydrofuran.
- the present invention also provides pharmaceutical compositions com ⁇ prising crystalline salts of (S) ( + )-8-chloro-5-(5,6-dichloro-2,3-dihydro- benzofuran-7-yl)-3-methyl-2,3,4,5-tetrahydro-1 H-3-benzazepine-7-ol and a pharmaceutically acceptable carrier.
- compositions of this invention are usually adapted for oral admini ⁇ stration, but formulations for dissolution for parenteral administration are also within the scope of this invention.
- composition is usually presented as a unit dose composition contain ⁇ ing 0.01 mg - 1000 mg for oral dosing.
- Typical dosage for antiphsy- chotic effect would vary between 0.1 - 400 mg, preferably between 1 .0 - 200 mg per day divided in 2 or 3 doses when administered orally.
- Preferred unit dosage forms include in solid form, tablets or capsules, in liquid form, solutions, suspensions, emulsions, elixirs or capsules filled with the same, or in form of sterile injectable solutions.
- composition of this invention may be formulated by conventional methods of galenic pharmacy.
- Conventional excipients are such pharmaceutically acceptable organic or inorganic carrier substances suitable for parenteral or oral application which do not deleteriously react with the active compound.
- examples of such carriers are water, salt solutions, alcohols, polyethylene glycols, polyhydroxyethoxylated castor oil, syrup, peanut oil, olive oil, gelatin, lactose, terra alba, sucrose, agar, pectin, acacia, amylose, magnesium stearate, talc, silicic acid, stearic acid, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, hydroxymethylcellulose and polyvinylpyrrolidone.
- the pharmaceutical preparations can be sterilized and mixed, if desired, with auxiliary agents, such as binders, lubricants, preservatives, dis- integrants, stabilizers, wetting agents, emulsifiers, salt for influencing osmotic pressure, buffers and/or colouring substances and the like, which do not deleteriously react with the active compound.
- auxiliary agents such as binders, lubricants, preservatives, dis- integrants, stabilizers, wetting agents, emulsifiers, salt for influencing osmotic pressure, buffers and/or colouring substances and the like, which do not deleteriously react with the active compound.
- injectable solutions or suspensions preferably aqueous solutions with the active compound dissolved in polyhydroxylated castor oil.
- tablets, dragees, or cap ⁇ sules having talc and/or a carbohydrate carrier or binder or the like, the carrier preferably being lactose and/or corn starch and/or potato starch.
- a syrup, elixir or like can be used when a sweetened vehicle can be employed.
- a typical tablet which may be prepared by conventional tabletting tech- niques, contains:
- the invention also provides methods of treatment of certain disorders in the central nerveous system related to dysfunctions of the dopamine D-1 receptor system, e.g. psychosis, depression, pain and Parkinson's disease in mammals including humans which methods comprises admini- stering an effective amount of a pharmaceutically acceptable crystalline salt of (S) ( + )-8-chloro-5-(5,6-dichloro-2,3-dihydrobenzofuran-7-yl)-3- methyl-2,3,4,5-tetrahydro- 1 H-3-benzazepine-7-ol.
- the invention further provides pharmaceutically acceptable crystalline salts of (S) ( + )-8-chloro-5-(5,6-dichloro-2,3-dihydrobenzofuran-7-yl)-3- methyl-2,3,4,5-tetrahydro-1 H-3-benzazepine-7-ol for use in the treatment of disorders in the central nerveous system related to dysfunctions of the dopamine D-1 receptor system, e.g. psychosis, depression, pain and Parkinson's disease.
- the preparation was carried out analogously to the preparation in Example 1 using L( + )-tartaric acid and 20 mmol of the compound of for ⁇ mula I .
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL12360296A IL123602A0 (en) | 1995-09-15 | 1996-09-12 | Salts of 2,3,4,5-Tetrahydro-1H-3-Benzazepine compounds |
| AU69235/96A AU700596B2 (en) | 1995-09-15 | 1996-09-12 | Acid addition salts of 2,3,4,5-tetrahydro-1H-3-benzazepine compounds |
| JP9511574A JPH11512403A (ja) | 1995-09-15 | 1996-09-12 | ２，３，４，５−テトラヒドロ−１ｈ−３−ベンズアゼピン化合物の酸付加塩 |
| CA002231848A CA2231848A1 (en) | 1995-09-15 | 1996-09-12 | Acid addition salts of 2,3,4,5-tetrahydro-1h-3-benzazepine compounds |
| EP96930028A EP0850237A1 (en) | 1995-09-15 | 1996-09-12 | Acid addition salts of 2,3,4,5-tetrahydro-1h-3-benzazepine compounds |
| PL96325514A PL325514A1 (en) | 1995-09-15 | 1996-09-12 | Addition salts formed with acids of 2,3,4,5-tetrahydro-1h-3-benzazepinic compounds |
| BR9610162A BR9610162A (pt) | 1995-09-15 | 1996-09-12 | Compostos uso de um sal cristalino composição farmacêutica processos para a preparação de sais de adição de ácido de um composto para o tratamento de uma indicação relacionada a disfunções do sistema receptor da dopamina D-1 em um mamífero e para a fabricação de uma composição farmacêutica |
| NO981135A NO981135D0 (no) | 1995-09-15 | 1998-03-13 | Syreaddisjonssalter av 2,3,4,5-tetrahydro-1H-3-benzazepinforbindelser |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK103095 | 1995-09-15 | ||
| DK1030/95 | 1995-09-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1997010239A1 true WO1997010239A1 (en) | 1997-03-20 |
Family
ID=8100205
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/DK1996/000383 WO1997010239A1 (en) | 1995-09-15 | 1996-09-12 | Acid addition salts of 2,3,4,5-tetrahydro-1h-3-benzazepine compounds |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP0850237A1 (cs) |
| JP (1) | JPH11512403A (cs) |
| KR (1) | KR19990044648A (cs) |
| CN (1) | CN1200121A (cs) |
| AU (1) | AU700596B2 (cs) |
| BR (1) | BR9610162A (cs) |
| CA (1) | CA2231848A1 (cs) |
| CZ (1) | CZ77898A3 (cs) |
| HU (1) | HUP9900746A3 (cs) |
| IL (1) | IL123602A0 (cs) |
| NO (1) | NO981135D0 (cs) |
| PL (1) | PL325514A1 (cs) |
| WO (1) | WO1997010239A1 (cs) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993017012A1 (en) * | 1992-02-24 | 1993-09-02 | Novo Nordisk A/S | 2,3,4,5-tetrahydro-1h-3-benzazepines and pharmaceutically acceptable acid addition salts thereof |
-
1996
- 1996-09-12 BR BR9610162A patent/BR9610162A/pt unknown
- 1996-09-12 CA CA002231848A patent/CA2231848A1/en not_active Abandoned
- 1996-09-12 IL IL12360296A patent/IL123602A0/xx unknown
- 1996-09-12 EP EP96930028A patent/EP0850237A1/en not_active Withdrawn
- 1996-09-12 HU HU9900746A patent/HUP9900746A3/hu unknown
- 1996-09-12 JP JP9511574A patent/JPH11512403A/ja active Pending
- 1996-09-12 CN CN96197660A patent/CN1200121A/zh active Pending
- 1996-09-12 PL PL96325514A patent/PL325514A1/xx unknown
- 1996-09-12 KR KR1019980701902A patent/KR19990044648A/ko not_active Withdrawn
- 1996-09-12 CZ CZ98778A patent/CZ77898A3/cs unknown
- 1996-09-12 AU AU69235/96A patent/AU700596B2/en not_active Ceased
- 1996-09-12 WO PCT/DK1996/000383 patent/WO1997010239A1/en not_active Application Discontinuation
-
1998
- 1998-03-13 NO NO981135A patent/NO981135D0/no unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993017012A1 (en) * | 1992-02-24 | 1993-09-02 | Novo Nordisk A/S | 2,3,4,5-tetrahydro-1h-3-benzazepines and pharmaceutically acceptable acid addition salts thereof |
Non-Patent Citations (1)
| Title |
|---|
| J. MED. CHEM., Vol. 25, 1982, CARL KAISER et al., "Absolute Stereochemistry and Dopaminergic Activity of Enantiomers of 2,3,4,5-Tetrahydro-7, 8-Dihydroxy-1-Phenyl-1H-3-Benzazepine", pages 697-703. * |
Also Published As
| Publication number | Publication date |
|---|---|
| BR9610162A (pt) | 1999-01-05 |
| AU700596B2 (en) | 1999-01-07 |
| HUP9900746A2 (hu) | 1999-09-28 |
| KR19990044648A (ko) | 1999-06-25 |
| CA2231848A1 (en) | 1997-03-20 |
| NO981135L (no) | 1998-03-13 |
| NO981135D0 (no) | 1998-03-13 |
| JPH11512403A (ja) | 1999-10-26 |
| CN1200121A (zh) | 1998-11-25 |
| EP0850237A1 (en) | 1998-07-01 |
| AU6923596A (en) | 1997-04-01 |
| PL325514A1 (en) | 1998-08-03 |
| IL123602A0 (en) | 1998-10-30 |
| CZ77898A3 (cs) | 1998-07-15 |
| MX9802000A (es) | 1998-08-30 |
| HUP9900746A3 (en) | 1999-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5958951A (en) | Modified form of the R(-)-N-(4,4-di(3-methylthien-2-yl)but-3-enyl)-nipecotic acid hydrochloride | |
| US5240933A (en) | 14-hydroxy-n-(2-methoxyethyl)-7,8-dihydromorphine and -norisomorphine, processes for the preparation thereof and the use thereof as pharmaceutical compositions | |
| EP0750616B1 (en) | Acid addition salts of 2,3,4,5-tetrahydro-1h-3-benzazepine compounds | |
| US4751222A (en) | 2,3,4,5-tetrahydro-1H-3-benzazepines and CNS affecting use thereof | |
| EP0766680A1 (en) | Substituted dihydrobenzofuran derivatives as 5-ht 4 agonists | |
| AU740958B2 (en) | N-substituted azaheterocyclic compounds | |
| MXPA02000033A (es) | Polimorfos de un diclorhidrato cristalino de azobiciclo (2, 2, 2)oct-3-ilamina y sus composiciones farmaceuticas. | |
| AU723267B2 (en) | Modified form of the R(-)-N-(4,4-di(3-methylthien-2-yl) but-3-enyl)-nipecotic acid hydrochloride | |
| WO1997010239A1 (en) | Acid addition salts of 2,3,4,5-tetrahydro-1h-3-benzazepine compounds | |
| US20110112145A1 (en) | Salts Of Methyl 2-((R))-(3-Chlorophenyl)((R)-1-((S)-2-(Methylamino)-3((R)-tetrahydro-2H-Pyran-3-YL)Propylcarbamoyl)Piperidin-3-YL)Methoxy)Ethylcarbamate | |
| NZ297312A (en) | 1-[2-phenyl-4-(4-(3-hydroxythien-2-yl)piperidino)butanoyl]azepane derivatives | |
| MXPA98002000A (en) | Salts of addition of acid of compounds of 2,3,4,5-tetrahidro-1h-3-benzacep | |
| MX2007010245A (es) | Sales de ocaperidona y composiciones farmaceuticas que contienen las mismas. | |
| JPH03197463A (ja) | 新規ベンズアゼピン | |
| SK13622000A3 (sk) | Kryštalická forma paroxetínu, farmaceutický prostriedok a použitie | |
| EP0333073A2 (en) | N-cycloalkylaminoethylbenzamide derivatives, their synthesis and pharmaceutical preparations | |
| JPH09507849A (ja) | 神経性情報の処理方法 | |
| EP1412350A1 (en) | Paroxetine isethionate salt, process of preparation and use in the treatment of depression | |
| HK1017343A (en) | Acid addition salts of 2,3,4,5-tetrahydro-1h-3-benzazepine compounds | |
| HUT70181A (en) | Novel arylpiperidine, process for producing thereof and pharmaceutical compositions comprising these compound | |
| WO2001025201A1 (en) | Process for the preparation of paroxetin intermediate | |
| EP0994869A1 (en) | 5-(2-ethyl-2h-tetrazol-5-y1)-1-methyl-1,2,3,6-tetrahydropyridine maleate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WWE | Wipo information: entry into national phase |
Ref document number: 96197660.8 Country of ref document: CN |
|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 1996930028 Country of ref document: EP |
|
| ENP | Entry into the national phase |
Ref document number: 2231848 Country of ref document: CA Ref document number: 2231848 Country of ref document: CA Kind code of ref document: A |
|
| ENP | Entry into the national phase |
Ref document number: 1997 511574 Country of ref document: JP Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: PV1998-778 Country of ref document: CZ Ref document number: PA/a/1998/002000 Country of ref document: MX Ref document number: 1019980701902 Country of ref document: KR |
|
| WWP | Wipo information: published in national office |
Ref document number: 1996930028 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: PV1998-778 Country of ref document: CZ |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| WWP | Wipo information: published in national office |
Ref document number: 1019980701902 Country of ref document: KR |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1996930028 Country of ref document: EP |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1019980701902 Country of ref document: KR |
|
| WWR | Wipo information: refused in national office |
Ref document number: PV1998-778 Country of ref document: CZ |